黎 書亮

Medicine & Life Sciences

1. SS-A antibodies 100%
2. lipoteichoic acid 97%
3. Artificial Intelligence 88%
4. Coronavirus 84%
5. Quercetin 77%
6. Acute Lung Injury 76%
7. Machine Learning 75%
8. Plasminogen Activator Inhibitor 1 75%
9. Adenocarcinoma of Lung 71%
10. Taiwan 66%
11. anti-IgG 62%
12. Hyperplasia 59%
13. Anti-Idiotypic Antibodies 56%
14. Pneumonia 54%
15. Vaccination 53%
16. Lung Neoplasms 53%
17. X-Rays 51%
18. SARS Virus 49%
19. Up-Regulation 48%
20. Thorax 46%
21. Systemic Lupus Erythematosus 42%
22. Non-Small Cell Lung Carcinoma 40%
23. Lung 39%
24. Biopsy 39%
25. Gram-Positive Bacteria 33%
26. B-Lymphocytes 29%
27. Clavicle 27%
28. Neoplasm Metastasis 27%
29. fibrin fragment D 26%
30. Psychology Transfer 26%
31. Triage 24%
32. Severe Acute Respiratory Syndrome 24%
33. Efficiency 24%
34. T-Lymphocytes 23%
35. Mechanical Ventilators 23%
36. Feasibility Studies 23%
37. Toll-Like Receptor 2 23%
38. Platelet Count 21%
39. Adult Respiratory Distress Syndrome 21%
40. Adenocarcinoma 21%
41. Ventilation 19%
42. Serum 19%
43. Solitary Pulmonary Nodule 19%
44. Therapeutics 19%
45. Plasma Cells 19%
46. Regulatory T-Lymphocytes 19%
47. Tomography 18%
48. Cell- and Tissue-Based Therapy 18%
49. SERPIN-B5 17%
50. Critical Illness 17%